Establishment of a drug sensitivity panel using human lung cancer cell lines

Akio Matsushita, Masahiro Tabata, Hiroshi Ueoka, Katsuyuki Kiura, Takuo Shibayama, Keisuke Aoe, Hiroyuki Kohara, Mine Harada

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We established a drug sensitivity panel consisting of 24 human lung cancer cell lines. Using this panel, we evaluated 26 anti-cancer agents: three alkylators, three platinum compounds, four antimetabolites, one topoisomerase I inhibitor, five topoisomerase II inhibitors, seven antimitotic agents and three tyrosine kinase inhibitors. This panel showed the following: a) Drug sensitivity patterns reflected their clinically-established patterns of action. For example, doxorubicin and etoposide were shown to be active against small cell lung cancer cell lines and mitomycin-C and 5-fluorouracil were active against non-small cell lung cancer cell lines, in agreement with clinical data. b) Correlation analysis of the mean graphs derived from the logarithm of IC50 values of the drugs gave insight into the mechanism of each drug's action. Thus, two drug combinations with reverse or no correlation, such as the combination of cisplatin and vinorelbine, might be good candidates for the ideal two drug combination in the treatment of lung cancer, as is being confirmed in clinical trials. c) Using cluster analysis of the cell lines in the panel with their drug sensitivity patterns, we could classify the cell lines into four groups depending on the drug sensitivity similarity. This classification will be useful to elucidate the cellular mechanism of action and drug resistance. Thus, our drug sensitivity panel will be helpful to explore new drugs or to develop a new combination of anti-cancer agents for the treatment of lung cancer.

Original languageEnglish
Pages (from-to)67-75
Number of pages9
JournalActa Medica Okayama
Volume53
Issue number2
Publication statusPublished - 1999

Fingerprint

Lung Neoplasms
Cells
Cell Line
Pharmaceutical Preparations
Drug Combinations
Topoisomerase I Inhibitors
Platinum Compounds
Topoisomerase II Inhibitors
Antimitotic Agents
Antimetabolites
Alkylating Agents
Small Cell Lung Carcinoma
Mitomycin
Etoposide
Drug Resistance
Cluster analysis
Non-Small Cell Lung Carcinoma
Fluorouracil
Protein-Tyrosine Kinases
Doxorubicin

Keywords

  • Drug resistance
  • Drug screening system
  • Lung cancer cell line
  • MTT assay

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Matsushita, A., Tabata, M., Ueoka, H., Kiura, K., Shibayama, T., Aoe, K., ... Harada, M. (1999). Establishment of a drug sensitivity panel using human lung cancer cell lines. Acta Medica Okayama, 53(2), 67-75.

Establishment of a drug sensitivity panel using human lung cancer cell lines. / Matsushita, Akio; Tabata, Masahiro; Ueoka, Hiroshi; Kiura, Katsuyuki; Shibayama, Takuo; Aoe, Keisuke; Kohara, Hiroyuki; Harada, Mine.

In: Acta Medica Okayama, Vol. 53, No. 2, 1999, p. 67-75.

Research output: Contribution to journalArticle

Matsushita, A, Tabata, M, Ueoka, H, Kiura, K, Shibayama, T, Aoe, K, Kohara, H & Harada, M 1999, 'Establishment of a drug sensitivity panel using human lung cancer cell lines', Acta Medica Okayama, vol. 53, no. 2, pp. 67-75.
Matsushita, Akio ; Tabata, Masahiro ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Shibayama, Takuo ; Aoe, Keisuke ; Kohara, Hiroyuki ; Harada, Mine. / Establishment of a drug sensitivity panel using human lung cancer cell lines. In: Acta Medica Okayama. 1999 ; Vol. 53, No. 2. pp. 67-75.
@article{bd0b51bf007244e7ae46097d716f85ad,
title = "Establishment of a drug sensitivity panel using human lung cancer cell lines",
abstract = "We established a drug sensitivity panel consisting of 24 human lung cancer cell lines. Using this panel, we evaluated 26 anti-cancer agents: three alkylators, three platinum compounds, four antimetabolites, one topoisomerase I inhibitor, five topoisomerase II inhibitors, seven antimitotic agents and three tyrosine kinase inhibitors. This panel showed the following: a) Drug sensitivity patterns reflected their clinically-established patterns of action. For example, doxorubicin and etoposide were shown to be active against small cell lung cancer cell lines and mitomycin-C and 5-fluorouracil were active against non-small cell lung cancer cell lines, in agreement with clinical data. b) Correlation analysis of the mean graphs derived from the logarithm of IC50 values of the drugs gave insight into the mechanism of each drug's action. Thus, two drug combinations with reverse or no correlation, such as the combination of cisplatin and vinorelbine, might be good candidates for the ideal two drug combination in the treatment of lung cancer, as is being confirmed in clinical trials. c) Using cluster analysis of the cell lines in the panel with their drug sensitivity patterns, we could classify the cell lines into four groups depending on the drug sensitivity similarity. This classification will be useful to elucidate the cellular mechanism of action and drug resistance. Thus, our drug sensitivity panel will be helpful to explore new drugs or to develop a new combination of anti-cancer agents for the treatment of lung cancer.",
keywords = "Drug resistance, Drug screening system, Lung cancer cell line, MTT assay",
author = "Akio Matsushita and Masahiro Tabata and Hiroshi Ueoka and Katsuyuki Kiura and Takuo Shibayama and Keisuke Aoe and Hiroyuki Kohara and Mine Harada",
year = "1999",
language = "English",
volume = "53",
pages = "67--75",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "2",

}

TY - JOUR

T1 - Establishment of a drug sensitivity panel using human lung cancer cell lines

AU - Matsushita, Akio

AU - Tabata, Masahiro

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Shibayama, Takuo

AU - Aoe, Keisuke

AU - Kohara, Hiroyuki

AU - Harada, Mine

PY - 1999

Y1 - 1999

N2 - We established a drug sensitivity panel consisting of 24 human lung cancer cell lines. Using this panel, we evaluated 26 anti-cancer agents: three alkylators, three platinum compounds, four antimetabolites, one topoisomerase I inhibitor, five topoisomerase II inhibitors, seven antimitotic agents and three tyrosine kinase inhibitors. This panel showed the following: a) Drug sensitivity patterns reflected their clinically-established patterns of action. For example, doxorubicin and etoposide were shown to be active against small cell lung cancer cell lines and mitomycin-C and 5-fluorouracil were active against non-small cell lung cancer cell lines, in agreement with clinical data. b) Correlation analysis of the mean graphs derived from the logarithm of IC50 values of the drugs gave insight into the mechanism of each drug's action. Thus, two drug combinations with reverse or no correlation, such as the combination of cisplatin and vinorelbine, might be good candidates for the ideal two drug combination in the treatment of lung cancer, as is being confirmed in clinical trials. c) Using cluster analysis of the cell lines in the panel with their drug sensitivity patterns, we could classify the cell lines into four groups depending on the drug sensitivity similarity. This classification will be useful to elucidate the cellular mechanism of action and drug resistance. Thus, our drug sensitivity panel will be helpful to explore new drugs or to develop a new combination of anti-cancer agents for the treatment of lung cancer.

AB - We established a drug sensitivity panel consisting of 24 human lung cancer cell lines. Using this panel, we evaluated 26 anti-cancer agents: three alkylators, three platinum compounds, four antimetabolites, one topoisomerase I inhibitor, five topoisomerase II inhibitors, seven antimitotic agents and three tyrosine kinase inhibitors. This panel showed the following: a) Drug sensitivity patterns reflected their clinically-established patterns of action. For example, doxorubicin and etoposide were shown to be active against small cell lung cancer cell lines and mitomycin-C and 5-fluorouracil were active against non-small cell lung cancer cell lines, in agreement with clinical data. b) Correlation analysis of the mean graphs derived from the logarithm of IC50 values of the drugs gave insight into the mechanism of each drug's action. Thus, two drug combinations with reverse or no correlation, such as the combination of cisplatin and vinorelbine, might be good candidates for the ideal two drug combination in the treatment of lung cancer, as is being confirmed in clinical trials. c) Using cluster analysis of the cell lines in the panel with their drug sensitivity patterns, we could classify the cell lines into four groups depending on the drug sensitivity similarity. This classification will be useful to elucidate the cellular mechanism of action and drug resistance. Thus, our drug sensitivity panel will be helpful to explore new drugs or to develop a new combination of anti-cancer agents for the treatment of lung cancer.

KW - Drug resistance

KW - Drug screening system

KW - Lung cancer cell line

KW - MTT assay

UR - http://www.scopus.com/inward/record.url?scp=0033111956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033111956&partnerID=8YFLogxK

M3 - Article

C2 - 10358721

AN - SCOPUS:0033111956

VL - 53

SP - 67

EP - 75

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 2

ER -